Kornimate/medical-research-clean huggingface dataset:
urologic-nephrological care of chronic kidney disease in saxony-anhalt/magdeburg.

Conditions: Chronic Kidney Disease (CKD)

Summary: statement: patients with chronic kidney disease (ckd) with an estimated glomerular filtration rate (egfr) under 60 ml/min using the mdrd-6 (modification of diet in renal disease) formula and/or ckd-epi (chronic kidney disease epidemiology collaboration) formula should undergo nephrological and urological care (diagnosis and treatment) to prevent chronic kidney failure. this is recommended by the national kidney foundation kidney disease outcomes quality initiative (kdoqi), kidney disease improving global outcomes (kdigo) and european urological association (eau). renal and postrenal diseases can cause or worsen ckd. internistic and intrarenal diseases can caused or worsen ckd. all diseases affecting ckd should be treated and the medical care should be optimized. hypothesis: not all patients with ckd receive urological and nephrological care. interdisciplinary work of outpatient working urologists and nephrologists in the metropolitan area magdeburg / saxony-anhalt germany is unknown. an descriptive analysis of interdisciplinary treatment connection of ckd patients for an orientating statement is needed.

the medical laboratory schenk-ansorge magdeburg saxony-anhalt germany receives all blood samples of outpatient patients of the medical practices of the metropolitan area magdeburg saxony-anhalt germany. every patient has a lifetime identification number independent of the submitting practice. every submitting medical doctor has a lifetime identification number and is identified by her/his medical subject /specialization. this analysis is based on that laboratory database. for that study a cohort of 1.031.336 patients from 12/2004 to 08/2014 is evaluated, that had been received blood tests with measurement of serum creatinine. for every serum creatinine an eggr is calculated with the guideline recommended formula.

Eligibility criteria:
inclusion criteria: * measured serum creatinine and estimated glomerular filtration rate * egfr \< 60 ml/min exclusion criteria: * dialysis * no serum creatinine measured * age \< 18 years

Keywords: chronic kidney disease urological care nephrological care
a study of mk0359 in patients with chronic obstructive pulmonary disease (copd)(0359-016)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: a study to test the effect of mk0359 in lessening the symptoms of copd as compared to salmeterol and placebo.


Eligibility criteria:
inclusion criteria: * you are between the ages of 40 and 75 * you have had a history for at least a year of copd symptoms * you have a history of smoking one pack of cigarettes per day for 10 years exclusion criteria: * you have been in a research study with an investigational drug or vaccine in the last 4 weeks. * you have donated blood in the last 4 weeks. * you have been hospitalized or had major surgery in the last 4 weeks * you have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your copd symptoms * you have a history of heart problems in the last 6 months * you have a history of stomach problems * you are unwilling to avoid grapefruit juice throughout the study
effects of preoperative anxiety and pain sensitivity in cases of endoscopic ultrasonography received sedoanalgesia

Conditions: Sedoanalgesia

Summary: the objective of this study was to detect whether preoperative anxiety and pain sensitivity had effects on the consumption of anesthetics, time to achieve desired level of sedation, patient and endoscopist satisfaction, and postoperative recovery time and pain in deep sedation.


Eligibility criteria:
inclusion criteria: * asa 1-2 category * between the ages of 20 and 65 * patients who has an education level and mental state to complete the scale and questionnaire provided for assessment exclusion criteria: * patients who has a psychiatric and neurological disease and use psychiatric drugs and chronic alcohol intake
analisis of facors involved in antidepressant treatment response of major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to predict and visualize sertraline treatment response in major depressive disorder with clinical symptoms, demographic and stress state, personality, eight genetic polymorphisms at baseline.

while only about 50% of patients respond to first treatment in major depressive disorder, 30-40% did not remit after continuous 1 year treatment. however, patients must remain on their prescribed medications for at least 4 weeks without knowing whether the particular antidepressant will be effective. studies have suggested a number of predictors of treatment response, but varying degrees of success and nearly all with poor prognostic sensitivity and specificity. the investigators investigated clinical symptoms, demographic and stress state, personality and genetic polymorphisms in patients of major depressive disorder treated with sertraline and performed multivariate analysis to extract the predicting factors. moreover, the investigators tried to visualize weight of variables and pathway one another.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of major depressive disorder * must be able to swallow tablets exclusion criteria: * pregnant * breastfeeding

Keywords: depression treatment response selective serotonin reuptake inhibitor
evaluation of antimicrobial photodynamic therapy and minimal intervention associated with deproteinization in permanent teeth with molar incisor hypomineralization

Conditions: Hypomineralization Molar Incisor

Summary: introduction: molar incisor hypomineralization (mih) is a qualitative defect of enamel development that occurs in the mineralization phase. mih affects one or more permanent molars and, occasionally, permanent incisors. the aim of the proposed study is to evaluate the clinical effect of antimicrobial photodynamic therapy (apdt) on permanent teeth with mih through decontamination and sensitivity control. the longevity of the restorations will also be evaluated after the deproteinization procedure. methods and analysis: patients 8 to 12 years of age with permanent molars will be randomly allocated to three groups. group 1: selective chemical-mechanical removal of carious dentinal tissue around the walls of the cavity with papacárie duo and a curette followed by the application of apdt and deproteinization with papacárie duo; group 2: selective removal of carious dentinal tissue around the walls of the cavity with a curette, followed by the application of apdt and deproteinization with a 5% sodium hypochlorite solution; group 3: selective removal of carious dentinal tissue using a curette. the selected teeth must have a carious lesion in the dentin and post-eruptive enamel breakdown on one or more surfaces with an indication for clinical restorative treatment. the teeth will subsequently be restored using a mixed technique with resin-modified glass ionomer cement and bulk-fill composite resin. the data will be submitted to descriptive statistical analysis. associations with age and sex will be tested using either the chi-squared test or fisher's exact test. pearson's correlation coefficients will be calculated to determine the strength of correlations between variables. comparisons of the microbiological results (colony-forming units) will be performed using anova and the kruskal-wallis test. kaplan-meier survival analysis will be performed to assess the performance of the restorations.


Eligibility criteria:
inclusion criteria: * healthy children with no adverse systemic conditions; * at least one permanent first molar with mih and active caries on the dentin with post-eruptive fracture on a single surface or multiple surfaces with an indication for restorative treatment; direct view and access; no clinical or radiographic signs or symptoms of pulpal involvement; * hypomineralized enamel with opacities near the margins of the cavities; * occurrence or non-occurrence of dentinal sensitivity. exclusion criteria: * clinically: carious lesion only involving the enamel, deficient restorations, small carious lesions in dentin (without access to manual excavator), hidden caries, clinical sign or symptom of pulpal involvement, clinical impossibility of restoration; * radiographically: evidence of pulpal involvement; * teeth severely affected by mih without indication for restorative treatment; * partially erupted teeth with mih.
fastwire revascularisation of extremities, (for lower limbs) - feasibility study (freeflow)

Conditions: Chronic Total Occlusion of Arteries of the Extremities

Summary: this study is to assess the safety and efficacy of the fastwire system. it is intended to assess that the fastwire system can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (ctos)

a first-in-human, single-arm, single-center, feasibility study to assess the efficacy and safety of the fastwire system in patients who have a chronic total occlusion in their peripheral vasculature causing an ischemic limb. the enrollment will consist of up to 10 patients meeting the inclusion/exclusion criteria.

Eligibility criteria:
inclusion criteria: 1. the patient, or the patient's legal guardian has signed and dated an informed consent form. 2. aged between 18 years and 85 years (inclusive). 3. severe claudication assessed as rutherford category 3 or clti assessed as rutherford category 4 or 5 lead. 4. angiographic confirmation of a de novo, cto, infrainguinal ligament including above the knee, below the knee, or below the ankle vessels. exclusion criteria: 1. life expectancy of less than 12 months. 2. females who are pregnant or lactating (urine test for women of childbearing age). 3. myocardial infarction or stroke in two months prior to the index procedure. 4. known, unstable coronary artery disease or other, uncontrolled comorbidity. 5. any known haemorrhagic or coagulation deficiency. 6. evidence of active infection, including but not limited to the target limb. 7. current use of cocaine or other substance of abuse. 8. patients who have received any thrombolytic therapy in the last two weeks. 9. history of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy. 10. subject participating in another study involving an investigational drug or device 11. patient has surgery or vascular intervention planned within 30 days of the index procedure. 12. patient has had a previous peripheral bypass that includes the target vessel. 13. patient has had a previous intervention in the target cto (angioplasty, stenting) including at time of index procedure. 14. patient tests positive for coronavirus disease (covid-2019), as per site standard practice. 15. estimated glomerular filtration rate (egfr) of less than 30 ml/min. 16. platelet count \< 50,000.

Keywords: chronic total occlusion peripheral cto fastwire system fastwire guidewire intra-luminal active wire procedure device
polarity therapy for american indian caregivers of dementia patients

Conditions: Stress; Depression; Anxiety

Summary: the purpose of this study is to assess the effectiveness of polarity therapy (pt), a complementary and alternative medicine treatment, in american indian caregivers living in the pacific northwest.

the caregivers of people with dementia experience high levels of stress and are at particularly high risk for physical and mental illness. although stress and illness are serious problems among american indian caregivers in the northwest, few studies have concentrated on this population. pt is a treatment that involves awareness of one's energy field and touch therapy; it has been shown to provide several physiological, biological, and psychological benefits. this study will determine whether pt is more effective than respite from caregiving in reducing stress, anxiety, and depression and improving health function and overall quality of life in american indian caregivers. participants will be randomly assigned to receive either eight weekly sessions of pt or 3 hours of weekly respite from caregiving for 8 weeks. at the beginning of the study and at weeks 4 and 8, participants will complete questionnaires and self-report scales on stress, anxiety, depression, and quality of life. in addition, heart rate variability and levels of cortisol will be measured at study entry and weeks 4 and 8.

Eligibility criteria:
inclusion criteria: * caregiver of a family member with dementia for at least 4 hours a day * american indian exclusion criteria: * nerve disorders caused by diabetes * use of beta blockers

Keywords: caregivers complementary therapies
comparison of the efficacy of intravenous paracetamol and ibuprofen in the treatment of fever due to upper respiratory tract infection

Conditions: Fever

Summary: currently, paracetamol, ibuprofen and nonsteroidal antiinflammatory drugs are widely used by emergency physicians in turkey for the treatment of fever . the objective of the study is compare the efficacy of intravenous ibuprofen and paracetamol in the treatment of patients with upper respiratory tract infections presenting with fever in the emergency department

this is the randomized double blinded clinical trial to compare the efficacy of these two drugs in this clinical setting. a randomized clinical trial was conducted in the emergency department (ed) of pamukkale university medical faculty hospital study personnel (emergency physicians and emergency service nurses) were trained before the study. when intravenous drugs (paracetamol and i̇buprofen) was being recommended, an eligibility checklist was completed by the attending physician. patients who presented to the emergency department with upper respiratory tract infection and had a temperature above 38.0 ° c were measured by a fever gauge included into the study first group: 1000 mg of paracetamol ( parol 10mg/ml solution mefar, turkey) intravenous (iv) was given 100 patients second group: ibuprofen 400 mg ( intrafen 400mg/4ml solution -gen ilaç san., turkey) intravenous (iv) was given 100 patients which determined to be applied as a group. drug packs prepared in 150 ml serum physiology were numbered by an independent nurse, who not involved in the study randomization was achieved by using computer software to generate random numbers. during the intervention, participants were monitored by an oxygen saturation (spo2) monitor, an automatic sphygmomanometer (blood pressure), and a rhythm monitor (heart rate and rhythms). patients in both groups received two types of medication in a similarmanner, thus ensuring double blind.

Eligibility criteria:
inclusion criteria: * patients who have fever for less than five days * at least 1 upper respiratory tract infection (urti) symptom according urti questionare exclusion criteria: * patients use anti-pyretic last 4 hours * to be pregnancy and breast-feeding patients of childbearing age who are not using a birth control method * patients with an allergy trait (paracetamol and ibuprofen) illiterates * hemodynamically unstable patients * patients with renal transplantation * patients with glucose 6 phosphate dehydrogenase (g6pd) deficiency * patients with non-controlled hypertension * patients with a history of cerebrovascular disease * patients with severe liver, kidney,pulmonary and cardiac heart failure * patients use antibiotics last 7 days * patients with wolff-parkinson-white syndrome or accompanying arrhythmias associated with conductive stimulus delivery in the heart * patients with vision problems

Keywords: fever, emergency department, paracetamol, ibuprofen, upper respiratory infection
parastop - paracetamol with strong opioids

Conditions: Cancer Pain; Cancer

Summary: current guidelines recommend all people with cancer-related pain should be prescribed paracetamol, even those receiving high doses of strong pain killers (opioids) such as morphine. although this has been shown in studies to be beneficial in other conditions, for instance dental work and after surgery, it has not been shown to further improve pain in people with cancer-related pain. taking tablets is burdensome to patients and the study aims to determine whether the inconvenience of taking eight extra paracetamol tablets per day can be justified. the study plans to show whether or not pain control is changed (non-inferior) when stopping paracetamol compared to continued use of paracetamol in people already taking strong pain killers for cancer-related pain. voluntary participants who are taking a combination of paracetamol and a strong opioid are recruited to the study.


Eligibility criteria:
inclusion criteria: * participants must be ≥ 18 years of age inclusive, at the time of signing the informed consent. * ≥50 kg (due to paracetamol dosage) * participants who are under palliative care or oncology service review * diagnosis of metastatic cancer * clinician-predicted life expectancy \>2 months * receiving daily regular strong opioids for cancer pain * receiving stable scheduled opioid dose last 48 hours\* * receiving paracetamol 1 gram x three or four times a day for at least five days * average pain intensity past 24 hours ≥ 2 and ≤ 7 (nrs 0-10)\* * able to take study drug/placebo as tablets * able to comply with all study procedures * capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol. * it is allowed to repeat procedure within the screening period without considering the participant being a rescreen exclusion criteria: * history of allergy or hypersensitivity to any of the active substances or excipients in the study drug * known severe liver or renal failure equivalent with ctcae grade 3 or 4\* precluding continuation of paracetamol. (\*common terminology criteria for adverse events (ctcae) version 5.0) * participants receiving subcutaneous, intravenous, intrathecal, or epidural opioid therapy * participants receiving systemic anticancer treatment during the intervention period if they are anticipated to have increasing pain or other symptoms related to the treatment * co-enrolment in other drug trials. participants will not be enrolled in any other on-going interventional clinical trial. study participants may be enrolled in non-interventional research (e.g. questionnaire, tissue collection studies) * previously enrolled in this study * pregnant or lactating women

Keywords: cancer pain pain analgesics sensory system agents physiological effects of drugs
race adiposity interactions regulate mechanisms determining insulin sensitivity

Conditions: Insulin Sensitivity; Fat; Liver

Summary: this research study will examine how ethnic/racial background, body composition (%body fat), and the location of body fat affect the ability of the hormone insulin to promote uptake of blood sugar in persons who are 19 to 45 years of age. when insulin is ineffective in promoting blood sugar uptake, this condition is termed "insulin resistance." insulin resistance plays a major role in the development of chronic metabolic diseases (such as type 2 diabetes, cardiovascular disease, and cancer), many of which differ with race. previous studies suggest that insulin resistance is higher in african-americans (aa) vs. european-americans (ea). however, results from these studies remain unclear due to different testing measures used for insulin resistance as well as differences in body fat between individuals. results from this research study may help explain why insulin resistance differs with genetic background and may guide development of personalized treatment strategies with implications for several chronic metabolic diseases (e.g., type 2 diabetes, cardiovascular disease, and cancer).

insulin resistance plays a major role in the etiology of chronic metabolic diseases, many of which differ with race/ethnicity. previous studies using mainly indirect methods suggest that insulin sensitivity is lower in aa vs. ea. our preliminary data using the reference standard glucose clamp indicate that in lean individuals, insulin sensitivity is lower among aa, while in obese individuals, insulin sensitivity is higher among aa. we hypothesize that this race/body mass index (bmi) interaction may be explained in part by significantly lower visceral and hepatic fat accumulation in aa. conversely, based on our preliminary data, we hypothesize that inherently greater oxidative stress impairs insulin sensitivity even in aa, explaining lower insulin sensitivity in lean aa vs. ea. we propose to test these hypotheses by prospectively comparing skeletal muscle and hepatic insulin sensitivity in healthy lean, overweight, and obese aa and ea using the hyperinsulinemic isoglycemic glucose clamp. analysis of ancestral genes will permit simultaneous assessment of the contribution of ancestry to main outcomes.

Eligibility criteria:
inclusion criteria: * african american or caucasian * body mass index 19-45 * do not have diabetes * exercise less than 2 hours per week * are willing to travel to uab for 2 screens and 4 testing visits exclusion criteria: * diabetes * any major medical conditions or medications that interfere with study outcomes
nutrition apps in occupational healthcare (pilot study of the foodnutri project)

Conditions: Occupational Diseases; Overweight and Obesity; Dyslipidemias; Hypertension; Diabete Type 2; Cardiovascular Diseases; Diet, Healthy; Diet Habit; Food Selection

Summary: the aim of this study is to investigate (1) the user experiences and usability of the nutrition apps (the finnish nutrition navigator and the finnish nutrition path) in occupational health care from the perspective of both professionals and customers, (2) the impact on diet, eating behavior, perceived well-being (perceived state of health, quality of life, work and functional ability) and anthropometric indicators compared to treatment as usual, and (3) cost-effectiveness of using the nutrition apps.

for the occupational healthcare customer, the study will include two visits to the occupational healthcare: at baseline and after a 12-week follow-up. first, all volunteer participants enrolled in the study will belong to the control group and they will get the treatment as usual. their weight, waist circumference, and blood pressure are measured at the visit and they are asked to answer a digital research questionnaire at both baseline and follow-up. the rest of the volunteer participants enrolled in the study will belong to the intervention group. before the visit at the occupational healthcare, they are asked to fill in the finnish nutrition navigator and to read the automated feedback about the diet quality. the finnish nutrition path can help in the dietary goal setting and it can be utilized together with the professional or independently. in addition, also weight, waist circumference, and blood pressure are measured at the visit and the participant is asked to answer a digital research questionnaire. the same procedure is done at both baseline and follow-up.

Eligibility criteria:
inclusion criteria: * employee of the certain employer * coming to the medical examination for employees whose work presents a special risk of illnessa or coming to the dietitian because of dyslipidemia, high blood pressure, weight loss, weight management, type 2 diabetes, cardiovascular disease * understands written finnish exclusion criteria: * pregnancy * eating disorder * severe challenges with diet (e.g., malabsorption, very restrictive diet due to several food allergies or other reasons)